Who Paid My Doc
Carlos Malvestutto
Infectious Disease Columbus, OH Medical Doctor
NPI 1548466022 CMS profile 1090459
700 Childrens Dr, Columbus, OH 43205
General payments
$70,037
Research payments
$34,157
Ownership & investment interest
$0
Research they led as principal investigator
$214,697
Through program year 2025, Carlos Malvestutto of Columbus, OH is reported in the CMS Open Payments database as having received $70,037 across 74 general payments and $34,157 in research payments paid to them. Separately, studies naming them as principal investigator received $214,697 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,867 | 18 | |
| 2024 | General | $2,140 | 3 | |
| 2023 | General | $12,518 | 5 | |
| 2022 | General | $10,892 | 8 | |
| 2021 | General | $9,350 | 4 | |
| 2020 | General | $13,871 | 19 | |
| 2020 | Research | $34,157 | 1 | |
| 2019 | General | $14,398 | 17 |
Beside peers
- Carlos Malvestutto
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Carlos Malvestutto were reported at $6,867. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Carlos Malvestutto | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $14,398 | $190 | $60–$862 | $163 |
| 2020 | $13,871 | $124 | $32–$606 | $114 |
| 2021 | $9,350 | $148 | $38–$905 | $132 |
| 2022 | $10,892 | $166 | $50–$834 | $149 |
| 2023 | $12,518 | $171 | $57–$787 | $160 |
| 2024 | $2,140 | $176 | $52–$752 | $164 |
| 2025 | $6,867 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 26 drugsPart D claims
1,042
Drug cost
$2,758,262
Branded share of claims
79.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 271 | $1,038,428 | |
| Rukobia Fostemsavir Tromethamine | Brand | 53 | $467,564 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 137 | $414,808 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 68 | $220,941 | |
| Tivicay Dolutegravir Sodium | Brand | 68 | $165,927 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 43 | $159,464 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 41 | $90,215 | |
| Prezcobix Darunavir/Cobicistat | Brand | 20 | $48,063 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 12 | $46,951 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 12 | $46,363 |
The 10 drugs with the highest cost, of 26 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 20 billing codesPaid by Medicare
$14,617
Medicare patients
88
Services billed
184
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Ischemic heart disease | 48% | |
| Chronic kidney disease | 43% | |
| Diabetes | 41% | |
| Depression | 40% | |
| Heart failure | 38% | |
| Atrial fibrillation | 34% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 12 | 13 | $1,967 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
75 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Infectious Disease in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.